Author:
Alshammari Mohammed Kanan,AlAtwi Noura Abdullah,Alshehri Wejdan Mohammed,Altwijri Shatha Khaled,Alsheehe Sama Abdulmohsen,Alshammari Abdulaziz Khalaf,Alroqi Rehab Raja,Alsharafi Raghad Othman,Alshehri Razan Ali,Alenazi Khalid Mokhlef,Alenazi Faisal shouick,Alenazy Nasser Hamdan,Alanazi Faisal Saleem,Aljasim Mujtaba Abbas Jasim,Alahmari Fatimah Raja
Abstract
Purpose: To evaluate the adverse events (AEs) associated with moxifloxacin (MFX) use in children below the age of 18 years.
Methods: This review was performed in conformity with the preferred items for systematic reviews and meta-analysis (PRISMA) guidelines using different databases. Articles meeting the inclusion criteria were screened and the studies were selected for the qualitative synthesis.
Results: A total of 21 studies were included in the systematic review. Among these, 7 retrospective cohort studies, 6 case reports, 3 prospective cohort studies, 2 randomized clinical trials (RCT) and the remainder utilized other methodologies. The variability in studies allowed for an assessment of the safety and tolerability of both short-term and long-term MFX administration in pediatric patients.
Conclusion: Although MFX use is associated with AEs, the majority were mild and resolved on their own. The reason for QTc prolongation and elevated liver enzymes remain a question for clinicians in prescribing MFX in pediatric patients.
Publisher
African Journals Online (AJOL)